Abstract

To the Editor: In the Japan Atrial Fibrillation Stroke Trial (JAST),1 aspirin at 150 to 200 mg per day does not seem to be either effective or safe for the prevention of stroke in patients with nonvalvular lone atrial fibrillation (AF). JAST is an important trial because many guidelines suggest that low risk patients with AF should be treated with aspirin, although the evidence, until recently, was limited. Previous studies already suggest that aspirin …

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.